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Between January 1988 and December 1992,68 patients admitted to our Department of Internal Medicine with 
haematological malignancies or solid tumours showed colonization of the respiratory tract with Stenotropho- 
monas maltophilia. To characterize the significance of respiratory tract colonization by S. maltophilia, we 
retrospectively reviewed the medical records of the 68 patients colonized with this organism. Twenty-nine of 
these 68 patients developed pneumonia, with S. maltophilia being implicated in 10 cases. The majority of these 
10 patients showed lobular infiltration on chest X-ray. Pleural effusion was observed in two (20%) of the 10 
patients. All 68 strains of S. maltophilia were resistant to imipenem. Latamoxef was effective against 98.5% of 
strains, while minocycline was effective against 100% of strains. This report describes the clinical features of 
nosocomial S. maltophilia pneumonia in immunocompromised patients. 
Introduction 
Stenotrophomonas maltophilia (formerly Xan- 
thomonas maltophilia) is an aerobic, glucose non- 
fermenting, gram-negative bacillus, which has 
become an important nosocomial pathogen in recent 
years (l-6). Stenotrophomonas maltophilia is isolated 
with increasing frequency, and strains are often 
resistant to antimicrobial agents that are used as 
initial treatment for gram-negative infections. How- 
ever, the clinical features of respiratory infection 
caused by S. maltophilia have not been well docu- 
mented (5-8). We report the clinical features of 
S. maltophilia pneumonia in immunocompromised 
patients. 
Materials and Methods 
PATIENTS 
Between January 1988 and December 1992, S. 
maltophilia was cultured from the upper respiratory 
tract of 68 patients admitted to the First Department 
of Internal Medicine, Kagawa Medical School, 
Japan. All patients were immunocompromised by 
haematological malignancies or solid tumours. 
Received 30 November 1994 and accepted in revised form 22 May 
1995. 
§Author to whom correspondence should be addressed at: First 
Department of Internal Medicine, Kagawa Medical School, 
Kagawa, 761-07, Japan. 
DIAGNOSIS OF NOSOCOMIAL PNEUMONIA 
(CASE DEFINITION) 
The diagnosis of infectious pneumonia combines 
clinical, laboratory and microbiological data. A 
compatible clinical picture (fever, cough and/or aus- 
cultatory findings such as rales and/or evidence of 
pulmonary consolidation), together with confir- 
matory chest radiographic findings and isolation of 
the causative pathogen(s) from suitable respiratory 
specimens (e.g. expectorated sputum, transtracheal 
aspirate, bronchial washings or lavage, pleural fluid) 
or blood, establishes the diagnosis of bacterial 
pneumonia (9). 
Sputum specimens were washed, gram stained and 
cultured quantitatively (10). Criteria for a final diag- 
nosis included isolation of the same organism from 
two or more consecutive coughed-up samples of 
sputum. To be considered as an aetiologic agent, this 
organism had to be present in cultures as the only or 
predominant organism (9,lO). In addition, micro- 
scopic examination of gram-stained smears of 
sputum should reveal gram-negative rods ingested by 
polymorphonuclear leucocytes (10). Only those con- 
sidered to have pneumonia caused by S. maltophilia 
were included here. 
Twenty-nine of 68 patients (42.6%) whose upper 
respiratory tracts were colonized with S. maltophilia 
developed pneumonia; however, other organisms 
might have been the causative agents in 19 cases. 
Therefore, we analysed the clinical features for the 
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Table 1 Characteristics of patients who developed Stenotrophomonas maltophilia pneumonia 
Quantitative C-reactive 
Age Date of cultures of Onset date protein WBCs 
Case and sex Underlying disease isolation sputum* of pneumonia (mg dl - ‘)t @l- i) Outcome 
1 56F 
2 71M 
3 61M 
4 51F 
5 64M 
6 65M 
7 79M 
8 41M 
9 53M 
10 59M 
Acute leukaemia 
Lung cancer 
Acute leukaemia 
Acute leukaemia 
Acute leukaemia 
Lung cancer 
Acute leukaemia 
Acute leukaemia 
Chronic leukaemia 
Acute leukaemia 
3/14/88 2+ 
1 l/25/88 3+ 
g/18/89 1+ 
914189 1+ 
512 l/90 1+ 
6/l 8/90 1+ 
7127190 1+ 
9/17/91 1+ 
10/29/91 2+ 
6/l/92 2+ 
3/13/88 
1 l/24/88 
9/l 1189 
9/l 1189 
5124190 
6/l 2190 
7/l 3/90 
9114191 
1 O/28/9 1 
6/l/92 
41 200 Dead 
17.5 300 Dead 
7.4 500 Dead 
6.2 1400 Alive 
14.7 200 Alive 
26.5 900 Dead 
18 600 Dead 
35 100 Alive 
17.1 100 Alive 
4.7 1100 Alive 
*l+, Less than 1 x 104; 2+, 1 x 10’ to 1 x 106; and 3+ more than 1 x 10’. tNorma1 range, 0.1-0.6mg dl-‘. M, male; 
F, female; WBCs, white blood cells. 
remaining 10 patients in whom S. maltophilia was the 
only organism isolated from the upper respiratory 
tract. An autopsy was performed in three of these 
10 patients. 
The clinical outcome was assessed according to 
whether the patient was eventually cured of the 
S. maltophilia pneumonia or died from it. Laboratory 
data, including the white blood cell (WBC) count and 
C-reactive protein (CRP) at the onset of pneumonia 
were recorded when available. Chest roentgenograms 
were reviewed in all patients. The type of lesion 
(unilateral or bilateral, lobular or lobar), lobes 
involved, and presence or absence of cavity forma- 
tion or pleural effusion were recorded. 
MICROBIOLOGICAL DATA 
To identify S. maltophilia, the VITEC identifi- 
cation card for gram-negative bacteria (bio Merieux 
Vitek, Inc., MO., U.S.A.) was used. 
All antimicrobial agents were obtained from their 
manufacturers in the form of standard laboratory 
powder and were stored at - 70°C before use. Anti- 
microbial susceptibility was determined by a stan- 
dard broth microdilution method as described by the 
National Committee for Clinical Laboratory Stan- 
dards. The minimum inhibitory concentrations of 13 
antibiotics to the S. maltophilia isolates were deter- 
mined by the MIC 2000 Plus System (Dynatech 
Laboratories, Inc., Alexandria, Va., U.S.A.). The 
following antibiotics were evaluated: piperacillin 
(PIPC); cefazolin (CEZ); cefotiam (CTM); sulbactaml 
cefoperazone (SBT/CPZ); latamoxef (LMOX); ceftazi- 
dime (CAZ); cefuzonam (CZON); amikacin (AMK); 
tobramycin (TOB); ofloxacin (OFLX); imipenem 
(IPM); carumonam (CRMN); and minocycline 
(MINO). 
Results 
PATIENT PROFILES 
The characteristics and clinical data of the 10 
patients who had S. maltophilia pneumonia are 
summarized in Table 1. Their underlying diseases in- 
cluded acute leukaemia (seven patients), lung cancer 
(two patients) and chronic myelogeneous leukaemia 
(one patient). In nine of these patients, S. maltophilia 
was first isolated from the upper respiratory tract 
from 1 week before to 1 week after the onset of 
pneumonia. Laboratory findings showed an elevation 
of CRP in all patients. The mean WBC count was 
5OO~ll’ (range lOO-14OOjKi). 
In this study, tracheal aspiration was also per- 
formed in five intubated patients after intubation 
because of exacerbation of pneumonia, and S. 
maltophilia was still cultured. In three patients (Cases 
2, 3 and 7), S. maltophilia was cultured from autop- 
sied lung tissues. The histology of lungs was basically 
consistent with usual bronchopneumonia. How- 
ever, infiltration of neutrophils was often relatively 
sparce, implying patients’ compromised states. Bacilli 
were observed in air spaces, and the lesions were 
accompanied by focal necrosis of haemorrhage. 
In one patient (Case S), S. maltophilia was cultured 
from the blood. However, his pneumonia improved 
by antibiotic treatment. 
Chest roentgenographic findings are summarized 
in Table 2. Five of the 10 patients had bilateral 
involvement. The presence of upper lobe involvement 
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Table 2 Chest roentgenographic findings of Stenotropho- 
monas maltophilia pneumonia 
No. of patients 
Location of infiltrates 
Bilateral 
Unilateral 
Distribution 
Right upper lobe 
Right middle lobe 
Right lower lobe 
Left upper lobe 
Left lower lobe 
Pattern 
Lobular 
Lobar and lobular 
Lobar 
Cavity formation 
Effusion 
Died of pneumonia 
5 
5 
6 
2 
5 
5 
7 
5 
2 
2 
0 
2 
5 
VS. lower lobe involvement was almost evenly 
distributed. A lobular pattern was observed in five 
patients; a combination of a lobular and lobar pat- 
tern in two patients, and a lobar pattern in two 
patients. Cavitation was not observed. Two of the 10 
patients had pleural effusions. 
Since S. maltophilia was the only isolated organism 
from the sputum, all patients received minocycline 
in addition to /3-lactams (latamoxef or sulbactam/ 
cefoperazone). Of the patients with pneumonia, five 
(50%) patients responded to antimicrobial therapy. 
Five patients died of respiratory failure caused 
by S. maltophilia pneumonia, while five patients 
survived. 
The antibiotic susceptibility of the 10 strains of 
S. maltophilia isolated in this survey was as follows: 
PIPC was effective against 40% (4/10) of strains; CEZ 
0% (0110); CTM 0% (O/10); SBT/CPZ 80% (8/10); 
LMOX 100% (10110); CAZ 70% (7110); CZON 
(HO); AMK 30% (3/10); TOB 10% (l/10); OFLX 
80% (8/10); IPM 0% (O/10); CRMN 100% (lo/lo); 
and MINO 100% (10110). 
Discussion 
This report describes the clinical features of 
Stenotrophomonas maltophilia pneumonia in immuno- 
compromised patients. Stenotrophomonas maltophilia 
is generally hospital-acquired and is most commonly 
isolated from patients with serious underlying 
diseases who have had prior antibiotic therapy, 
tracheotomy or endotracheal intubation, or genito- 
urinary instrumentation (11). 
As this organism has been considered to have a low 
virulence, S. maltophilia can colonize without causing 
pneumonia. Distinction between colonization and 
infection can be difficult. Among the early reports 
on S. maltophilia-related pneumonia, the evidence 
showing the aetiologic role of S. maltophilia was 
inconclusive (56). 
In the literature, reports of pneumonia caused by 
S. maltophilia failed to provide definitive evidence of 
infection as judged by isolation of the organism from 
sites that are normally sterile including lung tissue, 
pleural fluid and blood (56). However, more recent 
data demonstrate unequivocally that primary pul- 
monary infection is caused by S. maltophilia (7,8). In 
this survey, pneumonia occurred in 29 of 68 colon- 
ized patients, out of which 10 cases were considered 
to be caused solely by S. maltophilia. In three 
patients, S. maltophilia was cultured from autopsied 
lung tissues. 
While no roentgenographic presentation was 
diagnostic, certain informative patterns emerged: 
pleural effusion was present in two of 10 patients. 
Parenchymal infections were commonly lobular. 
The clinical course of S. maltophilia pneumonia 
was typical of severe bacterial infection with high 
fever and CRP elevation. Blood cultures were posi- 
tive in one of 10 patients. The mortality rate was 
50%, which is difficult to compare with other studies 
given the differences in patient populations. How- 
ever, this relatively high mortality rate, coupled with 
the lack of an effective antibiotic, may reflect the 
fact that the patients with S. maltophilia pulmonary 
infection tended to have other severe illnesses and 
malignant diseases in this study. 
The risk of S. maltophilia infection following ex- 
posure to broad spectrum antibiotics has been dem- 
onstrated in past studies (1,7). Exposure of IPM was 
the most important risk factor by comparison (12- 
14). Due to its broad spectrum of activity, coloniz- 
ation and superinfection with other bacteria are rare. 
In vitro, IPM has little or no activity against S. 
maltophilia and, therefore, superinfection with this 
organism is not surprising (12-14). In this study, IPM 
was used before the colonization of S. maltophilia in 
33 (48.5%) of 68 colonized patients. Other factors 
that contribute to a significant relative risk are the 
presence of central venous catheters, leukaemia as the 
underlying disease, neutropenia, and hospitalization 
for over 1 week (14-15). 
A hospital outbreak of S. maltophilia infection has 
been reported (16). In that report, patients with 
draining S. maltophilia surgical wound infections 
served as a reservoir for S. maltophilia, and the hands 
of hospital personnel were the vehicle for the 
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transmission of nosocomial S. maltophilia infections 
in the shock-trauma intensive care unit (16). 
Stenotrophomonas maltophilia has been isolated 
from the hospital environment in specimens from 
such areas as sink drains and respirators (15). Thus, 
the isolation of S. maltophilia from clinical specimens 
cannot always be equated with infection. A striking 
association has been reported between the use of 
equipment for respiratory therapy and the isolation 
of S. maltophilia from sputum; such an association 
suggests that this equipment may be a reservoir 
(5,15). In this study, although an environmental 
survey was performed, it was impossible to discover a 
common source of nosocomial infection. 
Treatment of S. maltophilia infection is made 
difficult by the almost universal resistance of this 
organism to the commonly used anti-pseudomonal 
agents. Stenotrophomonas maltophilia is resistant to 
commonly-used antimicrobial agents, including the 
one active against Pseudomonas aeruginosa (17). 
In addition, colonization and superinfection by S. 
maltophilia in patients who receive IPM, a broad- 
spectrum antibacterial agent to which S. maltophilia 
is inherently resistant, have been reported (15-17). 
Our data also showed that all 68 strains from 68 
colonized patients were resistant to IPM. The differ- 
ences in antimicrobial susceptibility patterns of vari- 
ous non-fermentative gram-negative organisms other 
than P. aeruginosa emphasize the necessity for careful 
speciation of this group of micro-organisms. The 
majority of patients described in this report had 
received or were receiving broad-spectrum antimicro- 
bial therapy at the time of isolation of S. maltophilia. 
In this study, LMOX, SBTKPZ, CRMN, and 
MINO were effective against clinical isolates of 
S. maltophilia. 
In summary, the results of this study demonstrate 
that S. maltophilia is a potential pathogen which 
can cause nosocomial pneumonia in immuno- 
compromised patients. 
References 
1. Gilardi GL, Pseudomonas maltophilia infections in man. 
Am J Clin Pathol 1969; 51: 58-61. 
2. Harlowe HD. Acute mastoiditis following Pseudomonas 
maltophilia infection: case report. Laryngoscope 1972; 
82: 882-883. 
3. Sutter VL. Identification of Pseudomonas species iso- 
lated from hospital environment and human sources. 
Appl Environ Microbial 1968; 16: 1532-1538. 
4. Ben-Tovim T, Eylan E, Roman0 A, Stein R. Gram- 
negative bacteria isolated from external eye infections. 
Infection 1974; 2: 162-165. 
5. Gardner P. Griffin WB. Swartz MN. Kunz LJ. Nonfer- 
6. 
7 
8 
9. 
10. 
Il. 
12. 
13. 
14. 
15. 
16. 
17. 
mentative gram-negative bacilli of nosocomial interest. 
Am J Med 1970; 48: 7355749. 
Sonnenwirth AC. Bacteremia with and without menin- 
gitis due to Yersinia enterocolitica, Edwardsiella tarda, 
Comamonas terrigena, and Pseudomonas maltophilia. 
Ann NY Acad Sci 1970; 174: 488-502. 
Zuravleff JJ, Yu VL. Infections caused by Pseudomonas 
maltophilia with emphasis on bacteremia: case reports 
and a review of the literature. Rev Infect Dis 1982; 4: 
12361246. 
Sarkar TK, Gilardi G, Aguam AS, Josephson J, 
Leventhal GL. Primary Pseudomonas maltophilia 
infection of the lung. Postgrad Med 1979; 65: 253-256. 
Wilson WR, Gilbert DN, Bisno AL et al. General 
guidelines for the evaluation of new anti-infective drugs 
for the treatment of respiratory tract infections, Clin 
Znfect Dis 1992; 15 (Suppl. 1): 62-88. 
Irifune K, Ishida T, Shimoguchi K et al. Pneumonia 
.-used by Stenotrophomonas maltophilia with a mucoid 
lenotype. J Clin Microbial 1994; 32: 28562857. 
Marshall WF, Keating MR, Anhalt JP, Steckelberg 
JM, Xanthomonas maltophilia: an emerging nosocomial 
pathogen. Mayo Clin Proc 1989; 64: 1097-1104. 
Park SY, Parker RH. Review of imipenem. Infect 
Control 1986; 7: 333-337. 
Jones RN. Review of the in vitro spectrum of activity of 
imipenem. Am J Med 1985; 78: 22232. 
Eliting LS, Khardori N, Bodey GP, Fainstein V. Noso- 
comial infection caused by Xanthomonas maltophilia: 
a case-control study of predisposing factors. Infect 
Control Hasp Epidemiol 1990; 11: 134138. 
Khardori N, Elting L, Wong E, Schable B, Bodey GP. 
Nosocomial infections due to Xanthomonas maltophilia 
(Pseudomonas maltophilia) in patients with cancer. Rev 
Infect Dis 1990; 12: 997-1003. 
Schable B, Villarino ME, Favero MS, Miller JM. 
Application of multilocus enzyme electrophoresis 
to - epidemiologic investigations of Xanthomonas 
maltouhilia. Infect Control HOSP Epidemiol 1991: 12: 
163-i67. ” 
_ _ 
Felegie TP, Yu VL, Rumans LM, Yee RB. Susceptibil- 
ity of Pseudomonas maltophilia to antimicrobial agents, 
singly and in combination. Antimicrob Agents Chem- 
other 1979; 16: 833-837. 
